Skip to content

Person-checked company records fromPerson-checked records $750See a worked exampleHuman review in progress

Talk to sales

KeptIndex

PTC Therapeutics, Inc.

Initiate the APHENITY registration-directed study for PTC923

Delivered after the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced
11 Jan 2021
Due
30 Jun 2021
Delivered
Q3 2021
  • Deadline
  • Met
  • Late
  • Not met
  • Today

What the company said

“A registration-directed study, APHENITY, for PTC923 in patients with phenylketonuria (PKU) is expected to initiate in mid-2021.”

What we found

Evidence strength A What the grades mean

The company missed the mid-2021 deadline, initiating the APHENITY trial in the third quarter of 2021 instead.

  • A
    PTC Therapeutics, Inc. 8-K filed 2021-07-29 Regulatory filing · published 29 Jul 2021 · retrieved 24 Oct 2026 · kept permanently by the SEC · fingerprint 39a934db7b37
    “The registration-directed Phase 3 PTC923 phenylketonuria (PKU) trial, APHENITY, is expected to initiate in the third quarter of 2021.” ✓ confirmed on the page
  • A
    PTC Therapeutics, Inc. 10-Q filed 2021-10-28 Regulatory filing · published 28 Oct 2021 · retrieved 24 Oct 2026 · kept permanently by the SEC · fingerprint 914c1e1c0a6c
    “The Company initiated a registration-directed Phase 3 trial for PTC923 for phenylketonuria (“PKU”) in the third quarter of 2021” ✓ confirmed on the page

Market reaction: the shares moved -1.7% against the S&P 500 over the three sessions around the disclosure (28 Jul 2021 to 2 Aug 2021). What this measures

Checked 24 Oct 2026.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type
Clinical milestone
Indicative materiality
Medium rules
Action
Initiate
Deliverable
APHENITY study for PTC923
Language
Expected (“expects”, “plans”)
In the company’s control
High
Specificity
High

How this entry was checked

  1. Commitment recordedThe company's words were matched word for word against the filing.
  2. First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
  3. Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you PTC Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2021-PTCT-021751 · Corrections policy

The Deadline Report

One email a week: the corporate commitments that came due, which were met, which slipped, and what is due next. Free. Stop any time.

No advertising. We never sell or share your address.